Intellia Presents New Research at AAAAI Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
Should l Buy NTLA?
Source: Newsfilter
- Clinical Trial Results: In a pooled Phase 1/2 analysis involving 32 hereditary angioedema (HAE) patients, a single 50 mg dose of lonvo-z resulted in a mean monthly attack rate of ≤0.2, representing a 96% reduction from baseline, highlighting the potential long-term safety and efficacy of lonvo-z.
- Evolving Treatment Goals: Among 28 patients who received lonvo-z, 86% achieved attack-free and long-term prophylaxis-free status after more than six months of follow-up, indicating a strong alignment between patient needs for reduced treatment burden and clinical objectives.
- Biological Modeling Study: Research indicates that significant C1-esterase inhibitor deficiency in HAE patients leads to excessive plasma kallikrein generation, with models showing that an 85% reduction in prekallikrein can normalize kallikrein and bradykinin levels, supporting the clinical efficacy of lonvo-z.
- Patient Challenge Survey: A survey of 100 HAE patients revealed that 34% experienced at least one attack per month, with only 20% being attack-free in the past year, underscoring the demand for lonvo-z as patients seek to eliminate chronic medication use to improve treatment outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 15.440
Low
4.00
Averages
16.50
High
54.00
Current: 15.440
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Presents New Research at AAAAI Meeting
- Clinical Trial Results: In a pooled Phase 1/2 analysis involving 32 hereditary angioedema (HAE) patients, a single 50 mg dose of lonvo-z resulted in a mean monthly attack rate of ≤0.2, representing a 96% reduction from baseline, highlighting the potential long-term safety and efficacy of lonvo-z.
- Evolving Treatment Goals: Among 28 patients who received lonvo-z, 86% achieved attack-free and long-term prophylaxis-free status after more than six months of follow-up, indicating a strong alignment between patient needs for reduced treatment burden and clinical objectives.
- Biological Modeling Study: Research indicates that significant C1-esterase inhibitor deficiency in HAE patients leads to excessive plasma kallikrein generation, with models showing that an 85% reduction in prekallikrein can normalize kallikrein and bradykinin levels, supporting the clinical efficacy of lonvo-z.
- Patient Challenge Survey: A survey of 100 HAE patients revealed that 34% experienced at least one attack per month, with only 20% being attack-free in the past year, underscoring the demand for lonvo-z as patients seek to eliminate chronic medication use to improve treatment outcomes.
See More
INTELLIA THERAPEUTICS STOCK RISES 2% FOLLOWING US FDA'S LIFTING OF CLINICAL HOLD ON HEART DISEASE GENE THERAPY TRIAL
- Stock Performance: Intelia Therapeutics shares increased by 2% following a positive development in their clinical trial results.
- Clinical Trial Focus: The trial is centered on gene therapy for treating heart disease, specifically targeting a gene associated with the condition.
See More
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
See More
Wall Street Analysts Adjust GE Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on General Electric (GE) stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Market Reaction Insight: While specific upgrades or downgrades were not provided, the change in analysts' perspectives could influence investor decisions, particularly among those considering purchasing GE stock.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in market dynamics, and investors should pay attention to these changes to make informed investment choices.
- Overall Market Trends: Changes in analyst ratings often signal market expectations regarding a company's future performance, thus investors should closely monitor these updates to seize potential investment opportunities.
See More
Intellia Therapeutics FDA Lifts Clinical Hold on Nexizuran Trials
- Clinical Trial Progress: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a 12% stock price increase on Monday, reflecting renewed market confidence in the drug.
- Historical Context: The clinical holds were imposed in October due to observed Grade 4 liver transaminase elevations and increased total bilirubin in a patient treated with nex-z, but both the MAGNITUDE and MAGNITUDE-2 trials have had their holds lifted, indicating progress in addressing safety concerns.
- Partnership Dynamics: The development of nex-z is in collaboration with Regeneron Pharmaceuticals, highlighting a joint effort to provide new treatment options for patients suffering from hereditary transthyretin amyloidosis with polyneuropathy, which could enhance patient outcomes.
- Financial Performance: Intellia reported a GAAP EPS of -$0.83 for Q4 2025, beating expectations by $0.12, while revenue reached $23.02M, exceeding forecasts by $10.85M, showcasing the company's potential in research and market expansion.
See More
Intellia Therapeutics Receives FDA Approval for Clinical Trial
- FDA Lifts Clinical Hold: The FDA has lifted the clinical hold on Intellia's MAGNITUDE trial, allowing the company to continue evaluating the efficacy and safety of nex-z in patients with transthyretin amyloidosis, which accelerates the advancement of its treatment options.
- Trial Enrollment Plans: Intellia aims to complete enrollment of approximately 1,200 patients in the MAGNITUDE trial and 60 patients in the MAGNITUDE-2 trial, ensuring data integrity and smooth trial progression, thereby laying the groundwork for future drug approval.
- Positive Stock Reaction: Intellia's shares rose 8.85% on Monday, reflecting a strong market reaction to the FDA's decision, with a 20% increase over the past 12 months indicating a favorable long-term trend for the company.
- Optimistic Analyst Ratings: The stock carries a Buy rating with an average price target of $19.73, with Chardan Capital and HC Wainwright & Co. maintaining and raising their targets, indicating strong market confidence in Intellia's future developments.
See More
Intellia Presents New Research at AAAAI Meeting
- Clinical Trial Results: In a pooled Phase 1/2 analysis involving 32 hereditary angioedema (HAE) patients, a single 50 mg dose of lonvo-z resulted in a mean monthly attack rate of ≤0.2, representing a 96% reduction from baseline, highlighting the potential long-term safety and efficacy of lonvo-z.
- Evolving Treatment Goals: Among 28 patients who received lonvo-z, 86% achieved attack-free and long-term prophylaxis-free status after more than six months of follow-up, indicating a strong alignment between patient needs for reduced treatment burden and clinical objectives.
- Biological Modeling Study: Research indicates that significant C1-esterase inhibitor deficiency in HAE patients leads to excessive plasma kallikrein generation, with models showing that an 85% reduction in prekallikrein can normalize kallikrein and bradykinin levels, supporting the clinical efficacy of lonvo-z.
- Patient Challenge Survey: A survey of 100 HAE patients revealed that 34% experienced at least one attack per month, with only 20% being attack-free in the past year, underscoring the demand for lonvo-z as patients seek to eliminate chronic medication use to improve treatment outcomes.
See More
INTELLIA THERAPEUTICS STOCK RISES 2% FOLLOWING US FDA'S LIFTING OF CLINICAL HOLD ON HEART DISEASE GENE THERAPY TRIAL
- Stock Performance: Intelia Therapeutics shares increased by 2% following a positive development in their clinical trial results.
- Clinical Trial Focus: The trial is centered on gene therapy for treating heart disease, specifically targeting a gene associated with the condition.
See More
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
See More
Wall Street Analysts Adjust GE Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on General Electric (GE) stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Market Reaction Insight: While specific upgrades or downgrades were not provided, the change in analysts' perspectives could influence investor decisions, particularly among those considering purchasing GE stock.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in market dynamics, and investors should pay attention to these changes to make informed investment choices.
- Overall Market Trends: Changes in analyst ratings often signal market expectations regarding a company's future performance, thus investors should closely monitor these updates to seize potential investment opportunities.
See More
Intellia Therapeutics FDA Lifts Clinical Hold on Nexizuran Trials
- Clinical Trial Progress: Intellia Therapeutics announced that the FDA has lifted the clinical hold on its phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), resulting in a 12% stock price increase on Monday, reflecting renewed market confidence in the drug.
- Historical Context: The clinical holds were imposed in October due to observed Grade 4 liver transaminase elevations and increased total bilirubin in a patient treated with nex-z, but both the MAGNITUDE and MAGNITUDE-2 trials have had their holds lifted, indicating progress in addressing safety concerns.
- Partnership Dynamics: The development of nex-z is in collaboration with Regeneron Pharmaceuticals, highlighting a joint effort to provide new treatment options for patients suffering from hereditary transthyretin amyloidosis with polyneuropathy, which could enhance patient outcomes.
- Financial Performance: Intellia reported a GAAP EPS of -$0.83 for Q4 2025, beating expectations by $0.12, while revenue reached $23.02M, exceeding forecasts by $10.85M, showcasing the company's potential in research and market expansion.
See More
Intellia Therapeutics Receives FDA Approval for Clinical Trial
- FDA Lifts Clinical Hold: The FDA has lifted the clinical hold on Intellia's MAGNITUDE trial, allowing the company to continue evaluating the efficacy and safety of nex-z in patients with transthyretin amyloidosis, which accelerates the advancement of its treatment options.
- Trial Enrollment Plans: Intellia aims to complete enrollment of approximately 1,200 patients in the MAGNITUDE trial and 60 patients in the MAGNITUDE-2 trial, ensuring data integrity and smooth trial progression, thereby laying the groundwork for future drug approval.
- Positive Stock Reaction: Intellia's shares rose 8.85% on Monday, reflecting a strong market reaction to the FDA's decision, with a 20% increase over the past 12 months indicating a favorable long-term trend for the company.
- Optimistic Analyst Ratings: The stock carries a Buy rating with an average price target of $19.73, with Chardan Capital and HC Wainwright & Co. maintaining and raising their targets, indicating strong market confidence in Intellia's future developments.
See More
